Valneva SE (FRA:AYJ)
4.854
+0.454 (10.32%)
Last updated: Aug 15, 2025
Valneva SE Employees
Valneva SE had 713 employees as of December 31, 2024. The number of employees increased by 37 or 5.47% compared to the previous year.
Employees
713
Change (1Y)
37
Growth (1Y)
5.47%
Revenue / Employee
€280,467
Profits / Employee
€95,773
Market Cap
812.23M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 713 | 37 | 5.47% |
Dec 31, 2023 | 676 | -43 | -5.98% |
Dec 31, 2022 | 719 | -43 | -5.64% |
Dec 31, 2021 | 762 | 262 | 52.40% |
Dec 31, 2020 | 500 | -21 | -4.03% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
SAP SE | 109,121 |
Siemens Aktiengesellschaft | 327,000 |
Deutsche Telekom AG | 198,194 |
Allianz SE | 156,626 |
Siemens Energy AG | 98,000 |
Rheinmetall AG | 28,539 |
Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 44,224 |
Deutsche Bank Aktiengesellschaft | 89,753 |
Valneva SE News
- 3 days ago - Valneva SE 2025 Q2 - Results - Earnings Call Presentation - Seeking Alpha
- 3 days ago - Valneva SE (VALN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 3 days ago - Valneva reports 1H results; reaffirms FY outlook - Seeking Alpha
- 3 days ago - Valneva Reports Half Year 2025 Financial Results and Provides Corporate Updates - Wallstreet:Online
- 3 days ago - Valneva Reports Half Year 2025 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 8 days ago - FDA lifts pause on Valneva's chikungunya vaccine in elderly - Seeking Alpha
- 8 days ago - Valneva Announces Removal of FDA-Recommended Pause on Use of Chikungunya Vaccine IXCHIQ in Elderly and Updates to the Prescribing Information - Wallstreet:Online
- 8 days ago - Valneva Announces Removal of FDA-Recommended Pause on Use of Chikungunya Vaccine IXCHIQ® in Elderly and Updates to the Prescribing Information - GlobeNewsWire